BCBS Arizona

Does BCBS Arizona cover Zepbound?

Quick answer · Weight Loss

BCBS Arizona does not cover it for weight loss on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Not covered. This PCG covers Zepbound only for the OSA indication. For use in weight loss, the document explicitly states 'please refer to the member's benefit plan book.' Weight loss coverage is not adjudicated under this PCG.
  • ACA Marketplace: Not covered. This PCG covers Zepbound only for the OSA indication. For use in weight loss, the document explicitly states 'please refer to the member's benefit plan book.' Weight loss coverage is not adjudicated under this PCG.

Last verified June 2, 2026. Policy effective February 20, 2025. Source: Download. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What BCBS Arizona requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Not covered

This PCG covers Zepbound only for the OSA indication. For use in weight loss, the document explicitly states 'please refer to the member's benefit plan book.' Weight loss coverage is not adjudicated under this PCG.

Policy note: This PCG explicitly defers Zepbound weight loss coverage to the member's benefit plan book. No PA criteria for the weight loss indication are established in this document.

Policy effective February 20, 2025 · verified June 2, 2026 · source: Download

ACA Marketplace

Not covered

This PCG covers Zepbound only for the OSA indication. For use in weight loss, the document explicitly states 'please refer to the member's benefit plan book.' Weight loss coverage is not adjudicated under this PCG.

Policy note: This PCG explicitly defers Zepbound weight loss coverage to the member's benefit plan book. No PA criteria for the weight loss indication are established in this document.

Policy effective February 20, 2025 · verified June 2, 2026 · source: Download

Zepbound for Osa

What BCBS Arizona requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI at or above the 95th percentile for age and sex
  • A1C no higher than 6.5%
  • 6 months of a documented diet and exercise program
  • Prior trial of Contrave, orlistat, phentermine, and Qsymia for at least 3 months
  • Prescribed by or in consultation with a specialist
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy
  • Lab results confirming eligibility
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Initial Approval: Zepbound for Moderate-to-Severe OSA with Obesity

All of:

  • Prescribed by or in consultation with a Pulmonologist or Sleep Medicine Physician
  • Diagnosis of moderate to severe obstructive sleep apnea in an individual with obesity
  • Age 18 years or older
  • Apnea Hypopnea Index (AHI) greater than 15 events/hour on polysomnogram
  • BMI >= 95th percentile (pediatric) OR BMI >= 30 kg/m2 (adult)
  • No concomitant use with GLP-1 agonists (e.g., Ozempic, Rybelsus, Trulicity, Mounjaro)
  • No FDA labeled contraindications (personal/family history of medullary thyroid carcinoma, MEN2, or prior serious hypersensitivity to GLP-1 receptor agonists)
  • No diagnosis of diabetes mellitus type 1 or type 2, history of ketoacidosis, hyperosmolar state/coma, or HbA1c > 6.5%
  • Not solely used for weight loss; must also be on appropriate therapy for OSA
  • Using PAP therapy unless medically contraindicated
  • Participating in a program supporting reduced calorie diet (>=500 kcal/day reduction) and physical activity (>=150 min/week)
  • Failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each
  • No severe gastrointestinal disease including severe gastroparesis, suicidal behavior or ideation, signs/symptoms of pancreatitis, gallbladder disease, or pregnancy

Plus any one of:

  • Failure (trial >= 3 months) of at least ONE non-GLP-1 weight loss medication: Contrave, orlistat, phentermine, or Qsymia
  • Contraindication to all listed non-GLP-1 weight loss medications
  • Intolerance to all listed non-GLP-1 weight loss medications

Continuation/Renewal: Zepbound for OSA

All of:

  • Continues to be seen by or in consultation with a Pulmonologist or Sleep Medicine Physician
  • Improvement in Apnea Hypopnea Index over baseline
  • Reduction of 5% or more in body weight from baseline
  • Documented adherence to prescribed therapy regimen
  • Continues reduced calorie diet (>=500 kcal/day reduction) and physical activity (>=150 min/week)
  • Failure, contraindication, or intolerance with THREE generic equivalents (if available) for at least 3 months each
  • No concomitant use with GLP-1 agonists
  • No new contraindications or significant adverse drug effects (pancreatitis, severe hypersensitivity, acute kidney injury, severe GI disease, drug-induced immune mediated thrombocytopenia, acute gallbladder disease)
  • No diagnosis of T1DM, T2DM, history of ketoacidosis, hyperosmolar state/coma, or HbA1c >= 6.5%
  • Not solely used for weight loss; must also be on appropriate therapy for OSA
  • Using PAP therapy unless medically contraindicated
  • Not currently taking any other drugs causing severe adverse reactions requiring discontinuation

Documentation to bring

  • Completed BCBSAZ prior authorization request form signed by prescribing provider
  • Chart notes documenting diagnosis of moderate to severe OSA with obesity
  • Lab results confirming Apnea Hypopnea Index (AHI) > 15 events/hour on polysomnogram
  • Documentation of BMI >= 30 kg/m2 (or >= 95th percentile for pediatric patients)
  • Paid claims or medical records confirming failure, contraindication, or intolerance to at least ONE non-GLP-1 weight loss medication (Contrave, orlistat, phentermine, or Qsymia) for at least 3 months
  • Documentation confirming failure, contraindication, or intolerance to THREE generic equivalents for at least 3 months each
  • Documentation confirming PAP therapy use or medical contraindication to PAP
  • Documentation of participation in reduced calorie diet and physical activity program
  • Documentation confirming no diagnosis of T1DM, T2DM, ketoacidosis, hyperosmolar state, or HbA1c > 6.5%
  • Documentation confirming prescriber is a Pulmonologist or Sleep Medicine Physician, or that prescription is in consultation with one
  • For continuation: chart notes with evidence of improvement in OSA (AHI improvement over baseline)
  • For continuation: documentation of >= 5% reduction in body weight from baseline
  • For continuation: lab values confirming safe use

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and Both of the following required: (1) improvement in Apnea Hypopnea Index over baseline, and (2) reduction of 5% or more in body weight from baseline. Documented adherence to prescribed therapy regimen, continued reduced calorie diet (at least 500 kcal/day reduction) and physical activity (at least 150 min/week) also required. Diabetes exclusion (T1DM, T2DM, HbA1c >=6.5%) and PAP therapy requirement are re-verified at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Type 2 diabetes mellitus
  • History of ketoacidosis
  • Hyperosmolar state/coma
  • HbA1c > 6.5%
  • Concomitant use with GLP-1 agonists (e.g., Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Prior serious hypersensitivity reaction (anaphylaxis, angioedema) to GLP-1 receptor agonists
  • Severe gastrointestinal disease including severe gastroparesis
  • Suicidal behavior or ideation
  • Signs and symptoms of pancreatitis
  • Gallbladder disease (cholelithiasis, cholecystitis)
  • Use solely for weight loss (must also be treating OSA)
  • Does not apply to Federal Employee Program, Medicare Advantage, Medicaid, or out-of-state BCBS plan members
  • Pregnancy
  • Type 1 diabetes

Policy note: PAP therapy is required unless medically contraindicated. Accepted PAP contraindications include: skin reactions or irritation, nasal polyposis/congestion/dryness unresponsive to nasal therapies, eye irritation from pressurized air, aerophagia, air leakage around device, psychosocial issues (claustrophobia, psychiatric disorders), and other physical limitations (arthritis, muscle weakness). The brand-specific criterion requires failure/contraindication/intolerance to THREE generic equivalents (if available) for at least 3 months each; FDA MedWatch reporting is expected for generic failures. Initial approval duration is 6 months or end of plan year; continuation approval is 12 months or end of plan year. Manufacturer assistance (coupons, samples) is NOT considered for continuation of therapy. For weight loss indication, the document explicitly directs to the member's benefit plan book rather than this PCG. OSA severity is defined by AHI > 15 events/hour (moderate to severe). The policy document is specific to Commercial and/or Marketplace plans only. Original effective date: 02/20/2025; Last criteria revision date: 08/21/2025.

Policy effective February 20, 2025 · verified June 2, 2026 · source: Download

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI at or above the 95th percentile for age and sex
  • A1C no higher than 6.5%
  • 6 months of a documented diet and exercise program
  • Prior trial of Contrave, orlistat, phentermine, and Qsymia for at least 3 months
  • Prescribed by or in consultation with a specialist
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy
  • Lab results confirming eligibility
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Initial Approval: Zepbound for Moderate-to-Severe OSA with Obesity

All of:

  • Prescribed by or in consultation with a Pulmonologist or Sleep Medicine Physician
  • Diagnosis of moderate to severe obstructive sleep apnea in an individual with obesity
  • Age 18 years or older
  • Apnea Hypopnea Index (AHI) greater than 15 events/hour on polysomnogram
  • BMI >= 95th percentile (pediatric) OR BMI >= 30 kg/m2 (adult)
  • No concomitant use with GLP-1 agonists (e.g., Ozempic, Rybelsus, Trulicity, Mounjaro)
  • No FDA labeled contraindications (personal/family history of medullary thyroid carcinoma, MEN2, or prior serious hypersensitivity to GLP-1 receptor agonists)
  • No diagnosis of diabetes mellitus type 1 or type 2, history of ketoacidosis, hyperosmolar state/coma, or HbA1c > 6.5%
  • Not solely used for weight loss; must also be on appropriate therapy for OSA
  • Using PAP therapy unless medically contraindicated
  • Participating in a program supporting reduced calorie diet (>=500 kcal/day reduction) and physical activity (>=150 min/week)
  • Failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each
  • No severe gastrointestinal disease including severe gastroparesis, suicidal behavior or ideation, signs/symptoms of pancreatitis, gallbladder disease, or pregnancy

Plus any one of:

  • Failure (trial >= 3 months) of at least ONE non-GLP-1 weight loss medication: Contrave, orlistat, phentermine, or Qsymia
  • Contraindication to all listed non-GLP-1 weight loss medications
  • Intolerance to all listed non-GLP-1 weight loss medications

Continuation/Renewal: Zepbound for OSA

All of:

  • Continues to be seen by or in consultation with a Pulmonologist or Sleep Medicine Physician
  • Improvement in Apnea Hypopnea Index over baseline
  • Reduction of 5% or more in body weight from baseline
  • Documented adherence to prescribed therapy regimen
  • Continues reduced calorie diet (>=500 kcal/day reduction) and physical activity (>=150 min/week)
  • Failure, contraindication, or intolerance with THREE generic equivalents (if available) for at least 3 months each
  • No concomitant use with GLP-1 agonists
  • No new contraindications or significant adverse drug effects (pancreatitis, severe hypersensitivity, acute kidney injury, severe GI disease, drug-induced immune mediated thrombocytopenia, acute gallbladder disease)
  • No diagnosis of T1DM, T2DM, history of ketoacidosis, hyperosmolar state/coma, or HbA1c >= 6.5%
  • Not solely used for weight loss; must also be on appropriate therapy for OSA
  • Using PAP therapy unless medically contraindicated
  • Not currently taking any other drugs causing severe adverse reactions requiring discontinuation

Documentation to bring

  • Completed BCBSAZ prior authorization request form signed by prescribing provider
  • Chart notes documenting diagnosis of moderate to severe OSA with obesity
  • Lab results confirming Apnea Hypopnea Index (AHI) > 15 events/hour on polysomnogram
  • Documentation of BMI >= 30 kg/m2 (or >= 95th percentile for pediatric patients)
  • Paid claims or medical records confirming failure, contraindication, or intolerance to at least ONE non-GLP-1 weight loss medication (Contrave, orlistat, phentermine, or Qsymia) for at least 3 months
  • Documentation confirming failure, contraindication, or intolerance to THREE generic equivalents for at least 3 months each
  • Documentation confirming PAP therapy use or medical contraindication to PAP
  • Documentation of participation in reduced calorie diet and physical activity program
  • Documentation confirming no diagnosis of T1DM, T2DM, ketoacidosis, hyperosmolar state, or HbA1c > 6.5%
  • Documentation confirming prescriber is a Pulmonologist or Sleep Medicine Physician, or that prescription is in consultation with one
  • For continuation: chart notes with evidence of improvement in OSA (AHI improvement over baseline)
  • For continuation: documentation of >= 5% reduction in body weight from baseline
  • For continuation: lab values confirming safe use

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and Both of the following required: (1) improvement in Apnea Hypopnea Index over baseline, and (2) reduction of 5% or more in body weight from baseline. Documented adherence to prescribed therapy regimen, continued reduced calorie diet (at least 500 kcal/day reduction) and physical activity (at least 150 min/week) also required. Diabetes exclusion (T1DM, T2DM, HbA1c >=6.5%) and PAP therapy requirement are re-verified at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Type 2 diabetes mellitus
  • History of ketoacidosis
  • Hyperosmolar state/coma
  • HbA1c > 6.5%
  • Concomitant use with GLP-1 agonists (e.g., Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Prior serious hypersensitivity reaction (anaphylaxis, angioedema) to GLP-1 receptor agonists
  • Severe gastrointestinal disease including severe gastroparesis
  • Suicidal behavior or ideation
  • Signs and symptoms of pancreatitis
  • Gallbladder disease (cholelithiasis, cholecystitis)
  • Use solely for weight loss (must also be treating OSA)
  • Does not apply to Federal Employee Program, Medicare Advantage, Medicaid, or out-of-state BCBS plan members
  • Pregnancy
  • Type 1 diabetes

Policy note: PAP therapy is required unless medically contraindicated. Accepted PAP contraindications include: skin reactions or irritation, nasal polyposis/congestion/dryness unresponsive to nasal therapies, eye irritation from pressurized air, aerophagia, air leakage around device, psychosocial issues (claustrophobia, psychiatric disorders), and other physical limitations (arthritis, muscle weakness). The brand-specific criterion requires failure/contraindication/intolerance to THREE generic equivalents (if available) for at least 3 months each; FDA MedWatch reporting is expected for generic failures. Initial approval duration is 6 months or end of plan year; continuation approval is 12 months or end of plan year. Manufacturer assistance (coupons, samples) is NOT considered for continuation of therapy. For weight loss indication, the document explicitly directs to the member's benefit plan book rather than this PCG. OSA severity is defined by AHI > 15 events/hour (moderate to severe). The policy document is specific to Commercial and/or Marketplace plans only. Original effective date: 02/20/2025; Last criteria revision date: 08/21/2025.

Policy effective February 20, 2025 · verified June 2, 2026 · source: Download

Why Zepbound requests get denied by BCBS Arizona

Based on what this policy asks for. Fix these before the first submission.

  1. Your plan's benefit excludes weight loss medications. A prior authorization cannot override a benefit exclusion — ask about a formulary exception or a different covered pathway.
  2. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  3. BMI not documented in the chart notes (or documented without a baseline weight and date).
  4. No documented diet and exercise program.
  5. Required prior medication trials not documented.
  6. Prescriber isn't the specialist the plan requires.
  7. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

BCBS Arizona has separate Zepbound policies that don't depend on the weight loss benefit:

  • Osa — covered on Employer / Commercial Insurance and ACA Marketplace.

Zepbound is also sold directly by Eli Lilly without insurance through LillyDirect.

Frequently asked questions

Does BCBS Arizona cover Zepbound?
BCBS Arizona does not cover it for weight loss on Employer / Commercial Insurance and ACA Marketplace.
How long does a Zepbound approval last with BCBS Arizona?
Initial approvals last 6 months, and renewals are granted in 12-month periods.
What does BCBS Arizona require to renew Zepbound?
At least 5% weight loss from the starting weight and Both of the following required: (1) improvement in Apnea Hypopnea Index over baseline, and (2) reduction of 5% or more in body weight from baseline. Documented adherence to prescribed therapy regimen, continued reduced calorie diet (at least 500 kcal/day reduction) and physical activity (at least 150 min/week) also required. Diabetes exclusion (T1DM, T2DM, HbA1c >=6.5%) and PAP therapy requirement are re-verified at continuation.
What if my plan excludes weight loss medications?
BCBS Arizona has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.
How current is this information?
This page reflects BCBS Arizona's written policy as of February 20, 2025, last verified against the source document on June 2, 2026.

Other medications under BCBS Arizona

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Arizona's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.